2017 ACVIM Forum Research Abstract Program

Pullout strength was greater with bicortical (4531 N +/-459 N) than monocortical implants (1783 N +/-459 N) regardless of implant type. There were no significant differences in pullout strength between implant type or vertebra, however, this may be due to low sample number. These data provide evidence that bicortical implant placement is a greater factor than the nature of the implant with respect to pullout strength in lumbar vertebral bodies, for those implants tested. The purpose of this study was to determine the pharmacokinetic profile and side effects following a single dose (500 mg) of extended release levetiracetam (XRL) in healthy cats. Seven healthy cats, weighing ≥5 kg were included. Health was determined by normal physical and neurologic examination, PCV/ TP and serum biochemistry evaluation. XRL was administered per os, with food, at time 0. Timed blood collection occurred over 36 hours via jugular catheter. Serum levetiracetam was quantitated by high performance liquid chromatography using a technique previously validated in cats. Data is reported as mean +/-SD. C max = 89.7 + /À25.7 lg/ ml, adjusted C max = 1.03 + /À0.27 lg/ml, T max =291.4 + /À94.4 minutes, MRT = 534.0 + /À61.7 minutes, CLss (compensated for F) = 0.001 + /À0.0005, C 12 hour = 43.7 + / À18.4 ug/ ml, C 24 hour = 4.9 + /À3.4 lg/ml, V d (adjusted for F) = 0.51 + /À0.11 L/kg, dose adjusted AUC = 676.5 + /À205.0 lg Á h/ ml. All cats had levetiracetam concentrations above the minimum human interval at 12 and 18 hours; 1 cat maintained levetiracetam concentrations above the interval at 24 hours. No adverse effects were noted throughout the study period and all cats maintained normal neurologic examinations. In conclusion, side effects appear to be minimal and the mean concentration at 24 hours was below the minimum human therapeutic interval by 0.1 lg/ml suggesting that once daily dosing may be possible however individual peak and trough serum concentrations should be considered when administered once daily. Osteosarcoma is the most common primary vertebral tumor in dogs, however previous studies examining outcome after surgical decompression of these tumors are limited. The goal of this study was to determine survival time after decompressive surgery alone and combined with adjunctive therapies such as definitive radiation or chemotherapy.